Abstract
Purpose of review To provide a comprehensive review of the available biomarkers for the detection and active surveillance of prostate cancer and simplify decision-making while choosing between them. Recent findings The limitations of PSA and mpMRI and the invasive nature of prostate biopsy has led to a constant search for serum and urinary biomarkers for both the detection and monitoring during active surveillance of prostate cancer. 4K, PHI and PCA3 have been validated in prospective clinical trials for initial detection of prostate cancer and recent evidence points to potential differentiation between indolent and aggressive cancer. However, the usage in monitoring tumor dynamics is debatable because of lack of conclusive evidence. The answer to the existing problems lies in high-quality studies to establish definitive evidence and also to help choose between the plethora of biomarkers available today. Summary Despite the advancements in innovation and usage of biomarkers in prostate cancer, there exists tremendous potential in improving them to fulfil the unmet need that exists today. Studies to establish conclusive evidence and integration with imaging can tremendously aid diagnosis and monitoring.
| Original language | English (US) |
|---|---|
| Journal | Current opinion in urology |
| DOIs | |
| State | Accepted/In press - Jan 1 2019 |
Fingerprint
Keywords
- active surveillance
- clinically significant cancer
- prostate cancer
- serum biomarkers
- urine biomarkers
ASJC Scopus subject areas
- Urology
Cite this
Serum and urinary biomarkers for detection and active surveillance of prostate cancer. / Becerra, Maria F.; Bhat, Abhishek; Mouzannar, Ali; Atluri, Venkatasai S.; Punnen, Sanoj.
In: Current opinion in urology, 01.01.2019.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Serum and urinary biomarkers for detection and active surveillance of prostate cancer
AU - Becerra, Maria F.
AU - Bhat, Abhishek
AU - Mouzannar, Ali
AU - Atluri, Venkatasai S.
AU - Punnen, Sanoj
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Purpose of review To provide a comprehensive review of the available biomarkers for the detection and active surveillance of prostate cancer and simplify decision-making while choosing between them. Recent findings The limitations of PSA and mpMRI and the invasive nature of prostate biopsy has led to a constant search for serum and urinary biomarkers for both the detection and monitoring during active surveillance of prostate cancer. 4K, PHI and PCA3 have been validated in prospective clinical trials for initial detection of prostate cancer and recent evidence points to potential differentiation between indolent and aggressive cancer. However, the usage in monitoring tumor dynamics is debatable because of lack of conclusive evidence. The answer to the existing problems lies in high-quality studies to establish definitive evidence and also to help choose between the plethora of biomarkers available today. Summary Despite the advancements in innovation and usage of biomarkers in prostate cancer, there exists tremendous potential in improving them to fulfil the unmet need that exists today. Studies to establish conclusive evidence and integration with imaging can tremendously aid diagnosis and monitoring.
AB - Purpose of review To provide a comprehensive review of the available biomarkers for the detection and active surveillance of prostate cancer and simplify decision-making while choosing between them. Recent findings The limitations of PSA and mpMRI and the invasive nature of prostate biopsy has led to a constant search for serum and urinary biomarkers for both the detection and monitoring during active surveillance of prostate cancer. 4K, PHI and PCA3 have been validated in prospective clinical trials for initial detection of prostate cancer and recent evidence points to potential differentiation between indolent and aggressive cancer. However, the usage in monitoring tumor dynamics is debatable because of lack of conclusive evidence. The answer to the existing problems lies in high-quality studies to establish definitive evidence and also to help choose between the plethora of biomarkers available today. Summary Despite the advancements in innovation and usage of biomarkers in prostate cancer, there exists tremendous potential in improving them to fulfil the unmet need that exists today. Studies to establish conclusive evidence and integration with imaging can tremendously aid diagnosis and monitoring.
KW - active surveillance
KW - clinically significant cancer
KW - prostate cancer
KW - serum biomarkers
KW - urine biomarkers
UR - http://www.scopus.com/inward/record.url?scp=85071500919&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85071500919&partnerID=8YFLogxK
U2 - 10.1097/MOU.0000000000000670
DO - 10.1097/MOU.0000000000000670
M3 - Review article
C2 - 31436568
AN - SCOPUS:85071500919
JO - Current Opinion in Urology
JF - Current Opinion in Urology
SN - 0963-0643
ER -